CORPORATE ACCESS

Company Intends to Meet with U.S. and EU Regulatory Authorities to Discuss Data from SHIELD I Phase 3 Study and Regulatory Pathway for D-PLEX100 in First Quarter of 2023 Implemented a Cost Reduction Plan, Including a 20% Decrease in Headcount Across All Departments...

PETACH TIKVA, Israel, Oct. 26, 2022 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its third quarter 2022 financial results and operational highlights...

Reduction of Approximately 20% in Organization Headcount Company Expects to Extend Cash Runway into Q3 2023 PolyPid Intends to Discuss Regulatory Pathway for D-PLEX100 for Prevention of Surgical Site Infections in Abdominal Surgery with U.S. and EU Regulatory...

Intends to discuss the Clinical Outcomes and Next Steps for D-PLEX100 for the Prevention of SSIs in Abdominal Surgery with the FDA and the EU Regulatory Authorities in Q1 2023 PETACH TIKVA, Israel, Sept. 19, 2022 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the...

Efficacy Data of D-PLEX100 in the Prevention of Post-Abdominal Surgery Incisional Infection will be Presented During a Podium Presentation PETACH TIKVA, Israel, Sept. 12, 2022 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company...

SHIELD I Study did not Achieve its Primary Endpoint of Reduction in Surgical Site Infections and Mortality In an FDA Requested Pre-specified Subgroup Analysis in Subjects with Incision Lengths over 20 centimeters (n=423), D-PLEX100 + SoC Achieved a Statistically...

Efficacy Data of D-PLEX100 in reduction of Surgical Site Infection in Surgical Trauma Injuries will be Presented During a Podium Presentation PETACH TIKVA, Israel, Aug. 30, 2022 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma...

Signed Exclusive Licensing Agreement for Commercialization of D-PLEX100 in Europe for Potentially Over $110 Million in Upfront and Milestone Payments, Plus Royalties on Net SalesIndependent Data Safety Monitoring Board Recommended Concluding Phase 3 SHIELD I Trial of...

PolyPid to potentially receive over $110 million in upfront and milestone payments as well as royalties on net sales ADVANZ PHARMA to receive exclusive rights to commercialize D-PLEX100 for the prevention of surgical site infections in abdominal and cardiac surgeries...

PETACH TIKVA, Israel, July 27, 2022 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its second quarter 2022 financial results and operational...

Efficacy Data of D-PLEX100 in the Prevention of Post-Abdominal Surgery Incisional Infection in High-Risk Patients will be Presented During a Podium Presentation PETACH TIKVA, Israel, July 25, 2022 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a...

Company Previously Announced Planned CEO Transition Following Retirement of Amir WeisbergPETACH TIKVA, Israel, July 05, 2022 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, announced...

PETACH TIKVA, Israel, June 15, 2022 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will host a key opinion leader ("KOL") webinar on the cost of managing surgical...

Phase 2 clinical data on the efficacy of D-PLEX100 in surgical site infection prevention in elective colorectal surgery will be presented during a poster presentation PETACH TIKVA, Israel, June 06, 2022 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a...

PETACH TIKVA, Israel, June 02, 2022 -- PolyPid Ltd. (Nasdaq: PYPD), ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will present at the JMP Securities 2022 Life Sciences Conference, which is...

Locally Administered Docetaxel Through Extended-Release Delivery via the Company's PLEX Technology Offers Potentially Enhanced Adjuvant Chemotherapy Option PETACH TIKVA, Israel, June 01, 2022 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage...

Following Unblinded Interim Efficacy Analysis, Data Safety Monitoring Board Recently Recommended Concluding Study at 950 Patients, the Minimum Number of Patients TargetedTop-line Results Expected by End of Q3 2022; Potential NDA and MAA Submissions Targeted for H1...

Enrollment of 950 Patients, the Minimum Number of Patients Targeted for the SHIELD I Study, Expected Within Days Top-line Results Expected by End of Q3 2022; Potential NDA and MAA Submissions Targeted for H1 2023 Conference Call Scheduled for Today at 8:30 a.m. ET...

Planned Unblinded Interim Analysis of Phase 3 SHIELD I Trial of D-PLEX100 in Abdominal Soft Tissue Surgery Expected to Occur Imminently Recruitment Progressing as Planned with Approximately 900 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX100 in Abdominal...

PETACH TIKVA, Israel, April 27, 2022 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its first quarter 2022 financial results and operational...

Presentation evaluates the effect of D-PLEX100 in limiting occurrence of antimicrobial resistance (AMR) in colorectal surgery patients PETACH TIKVA, Israel, April 25, 2022 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company...

Presentation evaluates the addition of D-PLEX to the surgical site infection standard of care prophylaxis regimen in elective colorectal surgeryPETACH TIKVA, Israel, April 12, 2022 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma...

Secured Loan facility with Kreos Capital Extends Company's Cash Runway into the Second Quarter of 2023PETACH TIKVA, Israel, April 06, 2022 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes,...

Presentation Evaluates Efficacy of D-PLEX100 in Reducing Surgical Site Infection Rates in Elective Colorectal Surgery PETACH TIKVA, Israel, March 08, 2022 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve...

Unblinded Interim Analysis Expected in the Second Quarter of 2022PETACH TIKVA, Israel, March 02, 2022 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a Phase 3 biopharmaceutical company focused on developing targeted, locally administered, and...

PETACH TIKVA, Israel, March 01, 2022 -- PolyPid Ltd. (Nasdaq: PYPD), ("PolyPid" or the "Company"), a Phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today...

FDA Agreed to PolyPid Request for the Addition of an Unblinded Interim Analysis in SHIELD I once 750 Patients Complete their 30-day Follow-up Recruitment Progressing as Planned with Approximately 680 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX100 in...

PETACH TIKVA, Israel, Jan. 26, 2022 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a Phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today...

Dr. Berger Brings Extensive Expertise in Deep Brain Tumor Treatment The Company Expects to Initiate a Phase 1/2 Clinical Trial of OncoPLEX for Brain Tumors by the end of 2022 PETAH TIKVA, Israel, Jan. 04, 2022 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the...

Current EVP & CFO, Dikla Czaczkes Akselbrad, Appointed CEO, Effective July 2022PETAH TIKVA, Israel, Jan. 03, 2022 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a Phase 3 biopharmaceutical company focused on developing targeted, locally administered,...

Company Continues to Expect that the Last Patient Will be Enrolled in the Second Quarter of 2022, Followed by Top-Line Results Two Months ThereafterPETAH TIKVA, Israel, Nov. 18, 2021 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a phase 3...

Company is Scheduled to Conduct Pre-IND Meeting with the U.S. FDA Later This Month and Potentially Initiate Phase 1/2 Clinical Trial of OncoPLEX for Brain Tumors in 2022PETAH TIKVA, Israel, Nov. 16, 2021 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a...

Recruitment Progressing as Planned with Approximately 480 Patients Enrolled in Phase 3 SHIELD I Trial of D-PLEX100 in Abdominal Surgery Following FDA Agreement that a Single Pivotal Phase 3 Study is Sufficient for Potential Approval of D-PLEX100 for the Prevention of...

PETAH TIKVA, Israel, Nov. 01, 2021 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today...

PETAH TIKVA, Israel, Sept. 20, 2021 -- PolyPid Ltd. (Nasdaq: PYPD), a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced its participation in...

Positive Results in Two Animal Models of Glioblastoma Multiform (GBM) demonstrated that Single Local Treatment of OncoPLEX Significantly Inhibited Tumor Growth and Prolonged SurvivalCompany Expects a Pre-IND Meeting with the U.S. FDA by Year End and Potential...

Virtual Presentation to be led by PolyPid Co-Founder and CSO on August 28, 2021PETACH TIKVA, Israel, Aug. 17, 2021 -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma focusing on developing targeted, locally administered and prolonged-release therapeutics to...

Recruitment Progressing as Planned with Over 300 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX100 in Abdominal Surgery FDA Agreed that a Single Pivotal Phase 3 Study is Sufficient for Potential Approval of D-PLEX100 for the Prevention of Surgical Site...

PETACH TIKVA, Israel, Aug. 09, 2021 -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, today announced that Executive Vice President and Chief...

PETAH TIKVA, Israel, July 28, 2021 -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, today announced that it will report its second quarter 2021...

PETAH TIKVA, Israel, July 12, 2021 -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company focusing on developing targeted, locally administered and prolonged-release therapeutics to improve surgical outcomes, today announced that it has appointed leading...

Presentation led by PolyPid EVP & CFO is taking place today on June 23, 2021 at 9:20am EDTPETAH TIKVA, Israel, June 23, 2021 -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered,...

PETAH TIKVA, Israel, June 02, 2021 -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, today announced that members of its executive management team...

FDA Agreed that a Single Pivotal Phase 3 Study is Sufficient for Potential Approval of D-PLEX100 for the Prevention of Surgical Site Infections in Colorectal Surgery. Enrollment in Phase 3 SHIELD I Trial of D-PLEX100 in Abdominal Surgery Continues to Advance; Over 200...

Recruitment Progressing as Planned with Nearly 200 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX100 in Abdominal Surgery Recruitment Rate in SHIELD I trial Doubled in the Last Three Weeks Manufacturing Facility Now Fully Scaled Up and Capable of Supporting...

PETAH TIKVA, Israel, April 29, 2021 -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, today announced that it will report its first quarter 2021...

PETAH TIKVA, Israel, Feb. 23, 2021 -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharmaceutical company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, today announced that it will present at the Raymond...

Top-line Data Anticipated by Year End 2021 Enrollment Also Continues to Progress in Company's Second Phase 3 Clinical Trial, SHIELD II PETAH TIKVA, Israel, Feb. 16, 2021 -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharmaceutical company aiming to improve surgical...

100 Patients Enrolled into Phase 3 SHIELD I and SHIELD II Trials of D-PLEX100 in Abdominal SurgeryRecently Initiated Phase 3 SHIELD II TrialGranted Breakthrough Therapy Designation from FDA for D-PLEX100 for Prevention of SSIs in Patients Undergoing Elective...

PETAH TIKVA, Israel, Jan. 27, 2021 -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced that it...